Antioxidants and polyunsaturated fatty acids in multiple sclerosis

European Journal of Clinical Nutrition

Volumn 59, Issue 12, 2005, Pages 1347-1361

  van Meeteren, M E ^a   Teunissen, C E ^b   Dijkstra, C D ^b   van Tol, E A F ^a  

^a NUMICO RESEARCH   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antioxidants; Demyelination; Dietary supplementation; Multiple sclerosis; Polyunsaturated fatty acids; Remyelination

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTIOXIDANT; APIGENIN; ASCORBIC ACID; BETA CAROTENE; CATALASE; CURCUMIN; DOCOSAPENTAENOIC ACID; FLAVONOID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; ICOSAPENTAENOIC ACID; INDOMETACIN; KAEMPFEROL; MEVINOLIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; QUERCETIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SATURATED FATTY ACID; SIMVASTATIN; SUPEROXIDE DISMUTASE; THIOCTIC ACID; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIOXIDANT ACTIVITY; CELL DAMAGE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHELATION; DEMYELINATION; DIETARY INTAKE; DISEASE MARKER; DRUG MECHANISM; ENZYME ACTIVITY; EXCITOTOXICITY; FOOD DRUG INTERACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NERVE FIBER; NONHUMAN; NUTRITIONAL DEFICIENCY; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SCAVENGING SYSTEM; SYMPTOMATOLOGY; TRANSCRIPTION REGULATION;

ANIMALS; ANTIOXIDANTS; DIETARY FATS, UNSATURATED; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FATTY ACIDS, UNSATURATED; HUMANS; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 31344438968     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602255     Document Type: Review

References (189)

1. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P & Rice-Evans CA (2002): Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med. 33, 1693-1702.
2. Alessandri JM, Poumes-Ballihaut C, Langelier B, Perruchot MH, Raguenez G, Lavialle M & Guesnet P (2003): Incorporation of docosahexaenoic acid into nerve membrane phospholipids: Bridging the gap between animals and cultured cells. Am. J. Clin. Nutr. 78, 702-710.
3. Barnett MH & Prineas JW (2004): Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann. Neurol. 55, 458-468.
4. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, Smith S, Woo E, Hawkins SA, Millar JH, Belin J, Conroy DM, Gill SK, Sidey M, Smith AD, Thompson RH, Zilkha K, Gale M & Sinclair HM (1989 : A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 52, 18-22.
5. Besler HT & Comoglu S (2003): Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr. Neurosci. 6, 189-196.
6. Besler HT, Comoglu S & Okcu Z (2002): Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr. Neurosci. 5, 215-220.
7. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB & Heales SJ (1997): Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 68, 2227-2240.
8. Bondy SC & LeBel CP (1993): The relationship between excitotoxicity and oxidative stress in the central nervous system. Free Radic. Biol. Med. 14, 633-642.
9. Bowen RA & Clandinin MT (2000): High dietary 18:3n-3 increases the 18:3N-3 but noN the 22:6n-3 content in the whole body, brain, skin, epididymal fat pads, and muscles of suckling rat pups. Lipids 35, 389-394.
10. Brand A, Gil S, Seger R & Yavin E (2001): Lipid constituents in oligodendroglial cells alter susceptibility to H2O2-induced apoptotic cell death via ERK activation. J. Neurochem. 76, 910-918.
11. Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM & Azzi A (2002): The European perspective Cn vitamin E: current knowledge and future research. Am. J. Clin. Nutr. 76, 703-716.
12. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, Giuffrida Stella AM & Pennisi G (2002): Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J. Neurosci. Res. 70, 580-587.
13. Cammer W (2002): Protection of cultured oligodendrocytes against tumor necrosis factor-alpha by the antioxidants coenzyme Q(10) and N-acetyl cysteine. Brain Res. Bull. 58, 587-592.
14. Canada AT, Giannella E, Nguyen TD & Mason RP (1990): The production of reactive oxygen species by dietary flavonols. Free Radic. Biol. Med. 9, 441-449.
15. Carreau JP (1979): Biosynthesis of lipoic acid via unsaturated fatty acids. Methods Enzymol. 62, 152-158.
16. Cherayil GD (1984): Sialic acid and fatty acid concentrations in lymphocytes, red blood cells and plasma from patients with multiple sclerosis. J. Neurol. Sci. 63, 1-10.
17. Choi C, Cho H, Park J, Cho C & Song Y (2003): Suppressive effects of genistein on oxidative stress and NFkappaB activation in RAW 264.7 macrophages. Biosci. Biotechnol. Biochem. 67, 1916-1922.
18. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW & Ames BN (1997): Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: Physiological implications. Proc. Natl. Acad. Sci. USA 94, 3217-3222.
19. Clandinin MT, Cheema S, Field CJ, Garg ML, Venkatraman J & Clandinin TR (1991):EDietary fat: exogenous determination of membrane structure and cell function. FASEB J. 5, 2761-2769.
20. Cohen G (1994): Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. Ann. NY Acad. Sci. 738, 8-14.
21. Cohly HH, Taylor A, Angel MF & Salahudeen AK (1998): Effect of turmeric, turmerin and curcumin on H2O2-induced renal epithelial (LLC-PK1) cell injury. Free Radic. Biol. Med. 24, 49-54.
22. Commandeur JN & Vermeulen NP (1996): Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26, 667-680.
23. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P & Moreau T (1998): Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339, 285-291.
24. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL & Tilton RG (1994): Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93, 2684-2690.
25. Cross AH, Manning PT, Stern MK & Misko TP (1997): Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J. Neuroimmunol. 80, 121-130.
26. Cunnane SC, Ho SY, Dore-Duffy P, Ells KR & Horrobin DF (1989): Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. Am. J. Clin. Nutr. 50, 801-806.
27. Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ & Miller DH (2002): Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 52, 47-53.
28. Datla KP, Christidou M, Widmer WW, Rooprai HK & Dexter DT (2001): Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport 12, 3871-3875.
29. Deigner HP, Haberkorn U & Kinscherf R (2000): Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin. Investig. Drugs 9, 747-764.
30. Deneke SM (2000): Thiol-based antioxidants. Curr. Top. Cell Regul. 36, 151-180.
31. DeWille JW & Farmer SJ (1992): Postnatal dietary fat influences mRNAS involved in myelination. Dev. Neurosci. 14, 61-68.
32. Di Biase A & Salvati S (1997): Exogenous lipids in myelination and demyelination. Kaohsiung J. Med. Sci. 13, 19-29.
33. Dimitrov NV, Meyer C, Gilliland D, Ruppenthal M, Chenoweth W & Malone W (1991): Plasma tocopherol concentrations in response to supplemental vitamin E. Am. J. Clin. Nutr. 53, 723-729.
34. Dworkin RH, Bates D, Millar JH & Paty DW (1984): Linoleic acid and multiple sclerosis: A reanalysis of three double-blind trials. Neurology 34, 1441-1445.
35. Eigner D & Scholz D (1999): Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J. Ethnopharmacol. 67, 1-6.
36. Emerit J, Edeas M & Bricaire F (2004): Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58, 39-46.
37. Ernst A, Stolzing A, Sandig G & Grune T (2004): Antioxidants effectively prevent oxidation-induced protein damage in OLN 93 cells. Arch. Biochem. Biophys. 421, 54-60.
38. Esparza ML, Sasaki S & Kesteloot H (1995): Nutrition, latitude, and multiple sclerosis mortality: An ecologic study. Am. J. Epidemiol. 142, 733-737.
39. Evans PH (1993): Free radicals in brain metabolism and pathology. Br. Med. Bull. 49, 577-587.
40. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R & Rice GP (2003): Interferons in relapsing remitting mulAiple sclerosis: a systematic review. Lancet 361, 545-552.
41. Fisher M, Levine PH, Weiner BH, Vaudreuil CH, Natale A, Johnson MH & Hoogasian JJ (1988): Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. Inflammation 12, 123-131.
42. Floris S, Blezer EL, Schreibelt G, Dopp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD & de Vries HE (2004): Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: A quantitative MRI study. Brain 127, 616-627.
43. Foot M, Cruz TF & Clandinin MT (1982): Influence of dietary fat on the lipid composition of rat brain synaptosomal and microsomal membranes. Biochem. J. 208, 631-640.
44. Fukuzawa K & Gebicki JM (1983): Oxidation of alpha-tocopherol in micelles and liposomes by the hydroxyl, perhydroxyl, and superoxide free radicals. Arch. Biochem. Biophys. 226, 242-251.
45. Fukuzawa K, Takase S & Tsukatani H (1985): The effect of concentration on the antioxidant effectiveness of alpha-tocopherol in lipid peroxidation induced by superoxide free radicals. Arch. Biochem. Biophys. 240, 117-120.
46. Gallai V, Sarchielli P, Trequattrini A & Murasecco D (1992): Supplementation of polyunsaturated fatty acids in multiple sclerosis. Ital. J. Neurol. Sci. 13, 401-407.
47. Gallai V, Sarchielli P, Trequattrini A, Franceschini M, Floridi A, Firenze C, Alberti A, Di Benedetto D & Stragliotto E (1995): Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J. Neuroimmunol. 56, 143-153.
48. Ghadirian P, Jain M, Ducic S, Shatenstein B & Morisset R (1998): Nutritional factors in the aetiology of multiple sclerosis: A case-control study in Montreal, Canada. Int. J. Epidemiol. 27, 845-852.
49. Gilgun-Sherki Y, Rosenbaum Z, Melamed E & Offen D (2002): Antioxidant therapy in acute central nervous system injury: Current state. Pharmacol. Rev. 54, 271-284.
50. Gilgun-Sherki Y, Melamed E & Offen D (2004): The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol. 251, 261-268.
51. Grant SM, Wiesinger JA, Beard JL & Cantorna MT (2003): Iron-deficient mice fail to develop autoimmune encephalomyelitis. J. Nutr. 133, 2635-2638.
52. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D & Adamson P (2003): Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17, 905-907.
53. Grimble RF (1998): Nutritional modulation of cytokine biology. Nutrition 14, 634-640.
54. Guy J, Qi X & Hauswirth WW (1998): Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA 95, 13847-13852.
55. Halliwell B (1992): Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
56. Harbige LS (1998): Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc. Nutr. Soc. 57, 555-562.
57. Harbige LS, Yeatman N, Amor S & Crawford MA (1995): Prevention of experimental autoimmune encephalomyelitis in Lewis rats by a novel fungal source of gamma-linolenic acid. Br. J. Nutr. 74, 701-715.
58. Harbige LS, Layward L, Morris-Downes MM, Dumonde DC & Amor S (2000): The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. Clin. Exp. Immunol. 122, 445-452.
59. Harrison EH & McCormick DB (1974): The metabolism of dl-(1,6-14C lipoic acid in the rat. Arch. Biochem. Biophys. 160, 514-522.
60. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ & Toyka KV (1992): Inflammatory mediators in demyelinating disorders of the CNS and PNS. J. Neuroimmunol. 40, 197-210.
61. Hemmer B, Archelos JJ & Hartung HP (2002): New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3, 291-301.
62. Hendriks JJ, de Vries HE, van der Pol SM, van den Berg TK, van Tol EA & Dijkstra CD (2003): Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem. Pharmacol. 65, 877-885.
63. Hendriks JJ, Alblas J, van der Pol SM, van Tol EA, Dijkstra CD & de Vries HE (2004): Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 200, 1667-1672.
64. Hertog MG, Hollman PC, Katan MB & Kromhout D (1993): Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer 20, 21-29.
65. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW & Deresinski SC (1997): Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl. Acad. Sci. USA 94, 1967-1972.
66. Hodnick WF, Kung FS, Roettger WJ, Bohmont CW & Pardini RS (1986): Inhibition of mitochondrial respiration and production of toxic oxygen radicals by flavonoids. A structure-activity study. Biochem. Pharmacol. 35, 2345-2357.
67. Holman RT, Johnson SB & Kokmen E (1989): Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proc. Natl. Acad. Sci. USA 86, 4720-4724.
68. Hollman PC & Katan MB (1998): Bioavailability and health effects of dietary flavonols in man. Arch. Toxicol. Suppl. 20, 237-248.
69. Hollman PC, Bijsman MN, van Gameren Y, Cnossen EP, de Vries JH & Katan MB (1999): The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic. Res. 31, 569-573.
70. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroski L, Farber JL, Akaike T, Maeda H & Koprowski H (1997): Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: Implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA 94, 2528-2533.
71. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I & Koprowski H (1998): Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 95, 675-680.
72. Hornig D (1975): Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann. NY Acad. Sci. 258, 103-118.
73. Jaruga E, Sokal A, Chrul S & Bartosz G (1998): Apoptosis-independent alterations in membrane dynamics induced by curcumin. Exp. Cell Res. 245, 303-312.
74. Jensen GE & Clausen J (1986): Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis - effects of antioxidant supplementation. Acta Pharmacol. Toxicol. (Copenh.) 59 (Suppl 7), 450-453.
75. Jimenez-Jimenez FJ, de Bustos F, Molina JA, de Andres C, Gasalla T, Orti-Pareja M, Zurdo M, Porta J, Castellano-Millan F, Arenas J & Enriquez de Salamanca R (1998): Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neurosci. Lett. 249, 65-67.
76. Joe B & Lokesh BR (1994): Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim. Biophys. Acta 1224, 255-263.
77. Joe B, Vijaykumar M & Lokesh BR (2004): Biological properties of curcumin-cellular and molecular mechanisms of action. Crit. Rev. Food Sci. Nutr. 44, 97-111.
78. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW & Schiffer RB (1995): Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276.
79. Jolivalt CG, Howard RB, Chen LS, Mizisin AP & Lai CS (2003): A novel nitric oxide scavenger in combination with cyclosporine A ameliorates experimental autoimmune encephalomyelitis progression in mice. J. Neuroimmunol. 138, 56-64.
80. Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R & Packer L (1992): Dihydrolipoic acid - a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem. Pharmacol. 44, 1637-1649.
81. Kallner A, Hartmann D & Hornig D (1977): On the absorption of ascorbic acid in man. Int. J. Vitam. Nutr. Res. 47, 383-388.
82. Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S & Vessby B (2000): Effects of dietary phenolic compounds on tocopherol, cholesterol, and fatty acids in rats. Lipids 35, 427-435.
83. Kandaswami C & Middleton Jr E (1994): Free radical scavenging and antioxidant activity of plant flavonoids. Adv. Exp. Med. Biol. 366, 351-376.
84. Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S & Vecsei L (1999): Nonenzymatic antioxidants of blood in multiple sclerosis. J. Neurol. 246, 533-539.
85. Kidd PM (2001): Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Altern. Med. Rev. 6, 540-566.
86. Kieseier BC & Hartung HP (2003): Multiple paradigm shifts in multiple sclerosis. Curr. Opin. Neurol. 16, 247-252.
87. Kim HK, Cheon BS, Kim YH, Kim SY & Kim HP (1999): Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264.7 and their structure-activity relationships. Biochem. Pharmacol. 58, 759-765.
88. Knight JA (1997): Reactive oxygen species and the neurodegenerative disorders. Ann. Clin. Lab. Sci. 27, 11-25.
89. Kobayashi MS, Han D & Packer L (2000): Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic. Res. 32, 115-124.
90. Kobuchi H, Virgili F & Packer L (1999): Assay of inducible form of nitric oxide synthase activity: Effect of flavonoids and plant extracts. Methods Enzymol. 301, 504-513.
91. Kornek B & Lassmann H (2003): Neuropathology of multiple sclerosis - new concepts. Brain Res. Bull. 61, 321-326.
92. Laidlaw M & Holub BJ (2003): Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women. Am. J. Clin. Nutr. 77, 37-42.
93. Langemann H, Kabiersch A & Newcombe J (1992): Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur. Neurol. 32, 248-252.
94. Lassmann H (1999): Mechanisms of demyelination and tissue damage in multiple sclerosis. Acta Neurol. Belg. 99, 6-10.
95. Lassmann H, Bruck W, Lucchinetti C & Rodriguez M (1997): Remyelination in multiple sclerosis. Mult. Scler. 3, 133-136.
96. Lee TH, Sethi T, Crea AE, Peters W, Arm JP, Horton CE, Walport MJ & Spur BW (1988): Characterization ofCleukotriene B3: comparison of its biological activities with leukotriene B4 and leukotriene B5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Clin. Sci. (Lond.) 74, 467-475.
97. Lehmann D, Karussis D, Misrachi-Koll R, Shezen E, Ovadia H & Abramsky O (1994): Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 50, 35-42.
98. Léwen A, Matz P & Chan PH (2000): Free radical pathways in CNS injury. J. Neurotrauma 17, 871-890.
99. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF & Lin JK (1999): Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20, 1945-1952.
100. Lim GP, Chu T, Yang F, Beech W, Frautschy SA & Cole GM (2001): The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
101. Lin RF, Lin TS, Tilton RG & Cross AH (1993): Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: An electron paramagnetic resonance study. J. Exp. Med. 178, 643-648.
102. Lipton SA & Rosenberg PA (1994): Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613-622.
103. Mai J, Sorensen PS & Hansen JC (1990): High dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol. Trace Element. Res. 24, 109-117.
104. Manach C, Scalbert A, Morand C, Remesy C & Jimenez L (2004): Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 79, 727-747.
105. Marracci GH, Jones RE, McKeon GP & Bourdette DN (2002): Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. 131, 104-114.
106. Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK & Bourdette DN (2004): Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res. 78, 362-370.
107. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A & Sanchez-Gomez MV (2001): The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 24, 224-230.
108. Mazzio E, Huber J, Darling S, Harris N & Soliman KF (2001): Effect of antioxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. Neurotoxicology 22, 283-288.
109. Merrill JE & Scolding NJ (1999): Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol. Appl. Neurobiol. 25, 435-458.
110. Merrill JE, Ignarro LJ, Sherman MP, Melinek J & Lane TE (1993): Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132-2141.
111. Mertin J & Stackpoole A (1978): Suppression by essential fatty acids of experimental allergic encephalomyelitis is abolished by indomethacin. Prostagland. Med. 1, 283-291.
112. Meydani SN (1996): Effect of (n-3) polyunsaturated fatty acids on cytokine production and their biologic function. Nutrition 12, S8-S14.
113. Meyer A, Buhl R, Kampf S & Magnussen H (1995): Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med. 152, 1055-1060.
114. Middleton Jr E, Kandaswami C & Theoharides TC (2000): The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52, 673-751.
115. Miksicek RJ (1995S: Estrogenic flavonoids: structural requirements for biological activity. Proc. Soc. Exp. Biol. Med. 208, 44-50.
116. Minghetti L & Levi G (1998): Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Prog. Neurobiol. 54, 99-125.
117. Molina-Holgado F, Hernanz A, De la Fuente M & Guaza C (1999): N-acetyl-cysteine inhibition of encephalomyelitis Theiler's virus-induced nitric oxide and tumour necrosis factor-alpha production by murine astrocyte cultures. Biofactors 10, 187-193.
118. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese M, Noonan D, Mancardi G, Albini A & Uccelli A (2004): Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148, 146-153.
119. 2+ toxicity in isolated hepatocytes. Biochim. Biophys. Acta 1052, 386-391.
120. Muthian G & Bright JJ (2004): Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 24, 542-552.
121. Nappi AJ & Vass E (1997): Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochim. Biophys. Acta 1336, 295-302.
122. Natarajan C & Bright JJ (2002): Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 168, 6506-6513.
123. Needleman P, Raz A, Minkes MS, Ferrendelli JA & Sprecher H (1979): Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. USA 76, 944-948.
124. Nightingale S, Woo E, Smith AD, French JM, Gale MM, Sinclair HM, Bates D & Shaw DA (1990): Red blood cell and adipose tissue fatty acids in mild inactive multiple sclerosis. Acta Neurol. Scand. 82, 43-50.
125. Nordvik I, Myhr KM, Nyland H & Bjerve KS (2000): Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand. 102, 143-149.
126. O'Brien NC, Charlton B, Cowden WB & Willenborg DO (1999): Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction. J. Immunol. 163, 6841-6847.
127. O'Brien NC, Charlton B, Cowden WB & Willenborg DO (2001): Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J. Immunol. 167, 5904-5912.
128. Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E & Atlas D (2004): A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J. Neurochem. 89, 1241-1251.
129. Oka A, Belliveau MJ, Rosenberg PA & Volpe JJ (1993): Vulnerability of oligodendroglia to glutamate: Pharmacology, mechanisms, and prevention. J. Neurosci. 13, 1441-1453.
130. Owens T (2003): The enigma oI multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr. Opin. Neurol. 16, 259-265.
131. Packer L, Witt EH & Tritschler HJ (1995): Alpha-Lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19, 227-250.
132. Packer L, Tritschler HJ & Wessel K (1997): Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic. Biol. Med. 22, 359-378.
133. Packer L, Weber SU & Rimbach G (2001): Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling. J. Nutr. 131, 369S-373S.
134. Pahan K, Sheikh FG, Namboodiri AM & Singh I (1998): N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic. Biol. Med. 24, 39-48.
135. Pan MH, Huang TM & Lin JK (1999): Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27, 486-494.
136. Pedchenko TV & LeVine SM (1998): Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J. Neuroimmunol. 84, 188-197.
137. Piani D & Fontana A (1994): Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J. Immunol. 152, 3578-3585.
138. Pitt D, Werner P & Raine CS (2000): Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 67-70.
139. Podda M, Weber C, Traber MG & Packer L (1996): Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols, and ubiquinones. J. Lipid Res. 37, 893-901.
140. Polman CH & Uitdehaag BM (2003): New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2, 563-566.
141. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E & Gil A (1999): Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147, 371-378.
142. Rice ME & Russo-Menna I (1998): Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 82, 1213-1223.
143. Richter C, Park JW & Ames BN (1988): Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. USA 85, 6465-6467.
144. Ruuls SR, Bauer J, Sontrop K, Huitinga I, t Hart BA & Dijkstra CD (1995): Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 56, 207-217.
145. Saija A, Scalese M, Lanza M, Marzullo D, Bonina F & Castelli F (1995 : Flavonoids as antioxidant agents: Importance of their interaction with biomembranes. Free Radic. Biol. Med. 19, 481-486.
146. Salvati S, Sanchez M, Campeggi LM, Suchanek G, Breitschop H & Lassmann H (1996): Accelerated myelinogenesis by dietary lipids in rat brain. J. Neurochem. 67, 1744-1750.
147. Schubert D & Piasecki D (2001): Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J. Neurosci. 21, 7455-7462.
148. Sen CK, Khanna S, Roy S & Packer L (2000): Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J. Biol. Chem. 275, 13049-13055.
149. Simopoulos AP (2002): Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21, 495-505.
150. Singh I, Pahan K, Khan M & Singh AK (1998): Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J. Biol. Chem. 273, 20354-20362.
151. Smith KJ,TKapoor R & Felts PA (1999): Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 9, 69-92.
152. Soliman KF & Mazzio EA (1998): In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc. Soc. Exp. Biol. Med. 218, 390-397.
153. Soliven B & Wang N (1995): Arachidonic acid inhibits potassium conductances in cultured rat oligodendrocytes. Am. J. Physiol. 269, C341-C348.
154. Song JH, Fujimoto K & Miyazawa T (2000): Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils. J. Nutr. 130, 3028-3033.
155. Soni KB & Kuttan R (1992): Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 36, 273-275.
156. Soudamini KK, Unnikrishnan MC, Soni KB & Kuttan R (1992): Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J. Physiol. Pharmacol. 36, 239-243.
157. Spitsin SV, Scott GS, Mikheeva T, Zborek A, Kean RB, Brimer CM, Koprowski H & Hooper DC (2002): Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic. Biol. Med. 33, 1363-1371.
158. Stanislaus R, Gilg AG, Singh AK & Singh I (2002): Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci. Lett. 333, 167-170.
159. Stüve O, Youssef S, Dunn S, Slavin AJ, Steinmann L & Zamvil SS (2003a): The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell Mol. Life Sci. 60, 2483-2491.
160. Stüve O, Youssef S, Steinman L & Zamvil SS (2003b): Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 16, 393-401.
161. Subramanian S, Matejuk A, Zamora A, Vandenbark AA & Offner H (2003): Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J. Immunol. 170, 1548-1555.
162. Suzuki YJ, Tsuchiya M & Packer L (1991): Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic. Res. Commun. 15, 255-263.
163. Swank R (1950)A Multiple sclerosis: a correlation of its incidence with dietary fat. Am. J. Med. Sci. 220, 421-430.
164. Takeda M & Soliven B (1997): Arachidonic acid inhibits myelin basic protein phosphorylation in cultured oligodendrocytes. Glia 21, 277-284.
165. TheriauAt A, Chao JT, Wang Q, Gapor A & Adeli K (1999): Tocotrienol: a review of its therapeutic potential. Clin. Biochem. 32, 309-319.
166. Torreilles F, Salman-Tabcheh S, Guerin M & Torreilles J (1999): Neurodegenerative disorders: The role of peroxynitrite. Brain Res. Brain Res. Rev. 30, 153-163.
167. van Acker SA, Tromp MN, Haenen GR, van der Vijgh WJ & Bast A (1995): Flavonoids as scavengers of nitric oxide radical. Biochem. Biophys. Res. Commun. 214, 755-759.
168. van Acker SA, van den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ & Bast A (1996): Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med. 20, 331-342.
169. van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK &
170. van Meeteren ME, Hendriks JJ, Dijkstra CD & van Tol EA (2004): Dietary compounds prevent oxidative damage and nitric oxide production by cells involved in demyelinating disease. Biochem. Pharmacol. 67, 967-975.
171. Van Oosten BW, Barkhof F & Polman CH (2004): New diagnostic criteria for multiple sclerosis in clinical practice. Ned. Tijdschr. Geneeskd 148, 1417-1422.
172. Vatassery GT (1998a): Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 53 (Suppl 1), S25-S27.
173. Vatassery GT, Nelson MJ, Maletta GJ & Kuskowski MA (1991): Vitamin E (tocopherols) in human cerebrospinal fluid. Am. J. Clin. Nutr. 53, 95-99.
174. Vatassery GT, Smith WE & Quach HT (1998b): Alpha-tocopherol in rat brain subcellular fractions is oxidized rapidly during incubations with low concentrations of peroxynitrite. J. Nutr. 128, 152-157.
175. Virgili F, Acconcia F, Ambra R, Rinna A, Totta P & Marino M (2004): Nutritional flavonoids modulate estrogen receptor alpha signaling. IUBMB Life 56, 145-151.
176. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M & Singh I (2004): Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608.
177. Wernerman J & Hammarqvist F (1999): Modulation of endogenous glutathione availability. Curr. Opin. Clin. Nutr. Metab. Care 2, 487-492.
178. Willenborg DO, Staykova MA & Cowden WB (1999): Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: A review. J. Neuroimmunol. 100, 21-35.
179. Wilson R & Tocher DR (1991): Lipid and fatty acid composition is altered in plaque tissue from multiple sclerosis brain compared with normal brain white matter. Lipids 26, 9-15.
180. Wong Jr EK, Enomoto H, Leopold IH, Williams JL, Kladde L & Hollander DH (1993): Intestinal absorption of dietary fat in patients with multiple sclerosis. Metab. Pediatr. Syst. Ophthalmol. 16, 39-42.
181. Woodruff RH & Franklin RJ (1997): Growth factors and remyelination in the CNS. Histol. Histopathol. 12, 459-466.
182. Wu D & Meydani SN (1998): N-3 polyunsaturated fatty acids and immune function. Proc. Nutr. Soc. 57, 503-509.
183. Xu LY, Yang JS, Link H & Xiao BG (2001): SIN-1, a nitric oxide donor, ameliorates experimental allergic encephalomyelitis in Lewis rats in the incipient phase: The importance of the time window. J. Immunol. 166, 5810-5816.
184. Yehuda S, Rabinovitz S, Mostofsky DI, Huberman M & Sredni B (1997): Essential fatty acid preparation improves biochemical and cognitive functions in experimental allergic encephalomyelitis rats. Eur. J. Pharmacol. 328, 23-29.
185. Youdim KA, Martin A & Joseph JA (2000): Essential fatty acids and the brain: Possible health implications. Int. J. Dev. Neurosci. 18, 383-399.
186. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L & Zamvil SS (2002): The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84.
187. Zafarullah M, Li WQ, Sylvester J & Ahmad M (2003): Molecular mechanisms of N-acetylcysteine actions. Cell Mol. Life Sci. 60, 6-20.
188. Zhang SM, Hernan MA, Olek MJ, Spiegelman D, Willett WC & Ascherio A (2001): Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 57, 75-80.
189. Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, Cross AH & Hickey WF (1996): Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J. Neuroimmunol. 64, 123-133.